Business Context and Reporting Period
This Form 6-K filing by Novo Nordisk A/S, dated September 30, 2024, reports on the company's ongoing share repurchase programme. Novo Nordisk is a leading global healthcare company headquartered in Denmark, employing approximately 69,000 people across 80 countries. The filing specifically details transactions executed under a programme initiated on August 7, 2024, which is part of a broader authorization to repurchase up to DKK 20 billion over a 12-month period starting February 6, 2024.
Key Financial Metrics
The filing focuses on capital allocation activities rather than operational financial performance. Key metrics include:
- Share Repurchase Programme Limit: Up to DKK 20 billion (12-month period from February 6, 2024).
- Specific Programme (Aug 7 - Nov 4, 2024): Up to DKK 2.4 billion.
- Accumulated Repurchases (as of Sept 27, 2024): 12,671,184 B shares.
- Total Transaction Value (since Feb 6, 2024): DKK 11,161,264,179.
- Average Purchase Price (since Feb 6, 2024): DKK 880.84 per B share.
- Treasury Shares Held: 13,999,815 B shares (0.3% of share capital).
- Total Share Capital: 4,465,000,000 A and B shares (including treasury shares).
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity for the reporting period.
Material Changes
Since the previous announcement on September 23, 2024, the company executed five additional transactions between September 23 and September 27, 2024. These transactions involved the purchase of 205,935 B shares at an average price ranging from DKK 805.09 to DKK 849.69, adding approximately DKK 171.7 million to the accumulated transaction value under the specific August programme.
Outlook and Management Commentary
Management reaffirms the expectation to repurchase B shares for an amount up to DKK 20 billion during the 12-month period beginning February 6, 2024. The company continues to execute the programme in accordance with the EU Market Abuse Regulation (MAR) and Safe Harbour Rules. No specific guidance on future earnings, risks, or contingencies is provided in this specific filing.
Investor Verification Checklist
- Verify the total amount repurchased against the DKK 20 billion authorization limit to assess remaining capacity.
- Confirm the current market price of B shares relative to the average purchase price of DKK 880.84.
- Review the full transaction history on novonordisk.com for granular daily data.
- Check the latest Form 20-F or quarterly reports for operational financial metrics (revenue, profit) not included in this 6-K.